MAP2K7 and melanoma: With the introduction of modern therapy strategies such as immune checkpoint inhibition (ICI) and BRAF/MEK-directed targeted therapy (TT), the prognosis of patients with advanced melanoma has improved significantly with response rates up to 70% and 5-year overall survival rates up to 50% (2–5).